Monitoring clinical trials. Interim data should not be publicly available.

Monitoring clinical trials. Interim data should not be publicly available.

Bibliografske podrobnosti
Glavni avtor:	Richards, S
Format:	Journal article
Jezik:	English
Izdano:	2001

Podobne knjige/članki

Issues in data monitoring and interim analysis of trials.
od: Grant, A, et al.
Izdano: (2005)

Issues in data monitoring and interim analysis of trials
od: A Grant, et al.
Izdano: (2005-03-01)

Interim monitoring of clinical trials: Decision theory, dynamic programming and optimal stopping
od: CHRISTOPHER JENNISON, et al.
Izdano: (2013-09-01)

Interim data monitoring to enroll higher-risk participants in HIV prevention trials
od: Umo-Otong John, et al.
Izdano: (2009-06-01)

Guidance on interim analysis methods in clinical trials
od: Jody D. Ciolino, et al.
Izdano: (2023-01-01)

Authors should make their data available.
od: Altman, D, et al.
Izdano: (2001)

Results availability and timeliness of registered COVID-19 clinical trials: interim cross-sectional results from the DIRECCT study
od: Salholz-Hillel, M, et al.
Izdano: (2021)

Results availability and timeliness of registered COVID-19 clinical trials: interim cross-sectional results from the DIRECCT study
od: Daniel Strech, et al.
Izdano: (2021-11-01)

Decision on performing interim analysis for comparative clinical trials
od: Kyongsun Pak, et al.
Izdano: (2017-09-01)

A comparative analysis of important public clinical trial registries, and a proposal for an interim ideal one.
od: Nisha Venugopal, et al.
Izdano: (2021-01-01)

Sharing some interim data in trial monitoring can mislead or unmask trial investigators: A scenario-based survey of trial experts
od: Victoria Borg Debono, et al.
Izdano: (2017-09-01)

Use of Accelerometer Activity Monitors to Detect Changes in Pruritic Behaviors: Interim Clinical Data on 6 Dogs
od: Susan M. Wernimont, et al.
Izdano: (2018-01-01)

The use of interim data and Data Monitoring Committee recommendations in randomized controlled trial reports: frequency, implications and potential sources of bias
od: Hampton John, et al.
Izdano: (2008-03-01)

Decision making in clinical trials: Interim analyses, innovative design, and biomarkers
od: Kathleen A. Welsh‐Bohmer, et al.
Izdano: (2023-10-01)

Interim analysis: A rational approach of decision making in clinical trial
od: Amal Kumar, et al.
Izdano: (2016-01-01)

Approaches to interim analysis of cancer randomised clinical trials with time to event endpoints: A survey from the Italian National Monitoring Centre for Clinical Trials
od: De Rosa Marisa, et al.
Izdano: (2008-07-01)

Estimation and Monitoring of COVID-19's Transmissibility From Publicly Available Data
od: Antonio Silveira, et al.
Izdano: (2020-11-01)

CANparent trial evaluation: First interim report
od: Cullen, M, et al.
Izdano: (2013)

Interim clinical trial analysis of intraoperative mass spectrometry for breast cancer surgery
od: Sankha S. Basu, et al.
Izdano: (2021-09-01)

CANparent trial evaluation: second interim report
od: Cullen, M, et al.
Izdano: (2014)

Availability of junk food should be reduced.
od: Tammam, J, et al.
Izdano: (2012)

Interim Report of the LOGO Project in the Brookline Public Schools
od: Members of the LOGO Project
Izdano: (2004)

Completeness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available data.
od: Beate Wieseler, et al.
Izdano: (2013-10-01)

Interim analyses of data as they accumulate in laboratory experimentation
od: Ludbrook John
Izdano: (2003-08-01)

Registration quality and availability of publications for clinical trials in Germany and the influence of structural factors.
od: Christian Thiele, et al.
Izdano: (2022-01-01)

Scoping review and characteristics of publicly available checklists for assessing clinical trial feasibility
od: Viktoria Gloy, et al.
Izdano: (2022-05-01)

Registration quality and availability of publications for clinical trials in Germany and the influence of structural factors
od: Christian Thiele, et al.
Izdano: (2022-01-01)

Should the impact factor of the year of publication or the last available one be used when evaluating scientists?
od: Gustavo A. Slafer, et al.
Izdano: (2020-12-01)

Laporan interim /
od: Universiti Teknologi Malaysia. Unit Penyelidikan dan Perundingan
Izdano: (1993)

Partnering with social service staff to implement pragmatic clinical trials: an interim analysis of implementation strategies
od: Lisa A. Juckett, et al.
Izdano: (2023-11-01)

Should data from demographic surveillance systems be made more widely available to researchers?
od: Chandramohan, D, et al.
Izdano: (2008)

Should data from demographic surveillance systems be made more widely available to researchers?
od: Chandramohan, D, et al.
Izdano: (2008)

Should data from demographic surveillance systems be made more widely available to researchers?
od: Daniel Chandramohan, et al.
Izdano: (2008-02-01)

Interim FDG-PET/CT for therapy monitoring and prognostication in Hodgkin’s Lymphoma
od: Akram Al-Ibraheem, et al.
Izdano: (2022-10-01)

Health data on public trial: To what extent should patients control access to patient records?
od: Malcolm Oswald, et al.
Izdano: (2017-04-01)

A randomised clinical trial of intrapartum fetal monitoring with computer analysis and alerts versus previously available monitoring
od: Santos Cristina, et al.
Izdano: (2010-10-01)

How large should a clinical trial be?
od: Pezeshk, H, et al.
Izdano: (2000)

PRISONS AND HEALTH Availability of junk food should be reduced
od: Tammam, J, et al.
Izdano: (2012)

Interim financial reporting
od: 6724 Lembaga Piawaian Perakaunan Malaysia
Izdano: (2001)

Direct current cardioversion during pregnancy should be performed with facilities available for fetal monitoring and emergency caesarean section.
od: Barnes, E, et al.
Izdano: (2002)